Neochem Bio IPO subscribed 1.29x on Day 2

Neochem Bio IPO subscription started on Tuesday, December 2, and the IPO will close on December 4, 2025, as per the schedule. The price band is set at ₹93 to ₹98 per share with a face value of ₹10.

Table of Contents

Neochem Bio IPO Subscription Status 

Neochem Bio IPO subscribed over 1.29x on its second day till 5.00 PM on December 3rd, 2025. 

  • Neochem Bio IPO subscription QIB investors’ portion was 1.23 times, while NII was subscribed 2.00 times, and RII investors subscribed 1.01 times. 
  • The company has received bids for 39,27,600 shares against 30,52,800 shares on offer for the second-day subscription. 
  • Neochem Bio IPO subscribed over 1.29x on its day 2. 
  • Neochem Bio IPO subscribed over 0.77x on its day 1.  

About Neochem Bio Company 

Neochem Bio Solutions Ltd was incorporated in 2006, involved in the manufacturing of specialty performance chemicals with over 40 years of experience. The firm provides more than 350 customised chemical products across 4 categories: Polymers, Surfactants, Silicones, and Esters & bio-based solutions.

The company’s products are used in various industries such as textile and garment washing, home and personal care, industrial and institutional cleaning, water treatment, paints and coatings, paper and pulp, construction, rubber, and dyes and pigments. Moreover, Neochem also provides textile and garment auxiliaries, which are utilized for pre-treatment, dyeing, finishing, printing, and coating work in all types of fabrics and garments. Its manufacturing facility is located at Saket Industrial Estate, Moraiya, Sanand, Ahmedabad, with an installed capacity of 22,000 MTPA and covers an area of 6,763 square meters. 

Neochem Bio IPO GMP:  

Neochem Bio IPO GMP was ₹0 as of Wednesday, December 3, 2025. That indicates the IPO is trading at ₹98 with a ₹0 premium in the grey market against the issue price of ₹98.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *